Elevation Oncology, Inc. announced on April 25, 2025, new preclinical proof-of-concept data for its novel HER3 antibody-drug conjugate (ADC), EO-1022. The data were presented in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025.
The preclinical findings indicated enhanced stability and anti-tumor activity for EO-1022 compared to benchmark HER3 ADCs in both in vitro and in vivo models. EO-1022 is designed with glycan site-specific conjugation and MMAE payloads, leveraging technology licensed from Synaffix B.V.
Elevation Oncology is developing EO-1022 for the treatment of HER3-expressing solid tumors, including breast cancer and non-small cell lung cancer. The company remains on track to file an Investigational New Drug (IND) application for EO-1022 in 2026, advancing it towards clinical evaluation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.